newsfilter
← Latest News
PR Newswire·

Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton

IMUX
  • Immunic, Inc. (Nasdaq: IMUX) appointed Jon Congleton to its Board of Directors effective March 27, 2026.
  • Congleton brings nearly 40 years of biopharmaceutical experience spanning drug development, commercialization, & corporate leadership in CNS, cardiovascular, & gastrointestinal sectors.
  • He served on the original team responsible for launching Copaxone® in the U.S. & led U.S. operations when it became the top prescribed MS treatment.
  • Currently, Congleton serves as CEO & Board member of Mineralys Therapeutics, Inc., guiding it from a private entity to a publicly traded firm.
  • His previous leadership roles include CEO positions at Impel NeuroPharma, Inc. & Nivalis Therapeutics, Inc., along with senior roles at Teva Pharmaceuticals leading U.S. & Canadian neuroscience businesses.
  • Immunic Interim Board Chair Simona Skerjanec highlighted Congleton's deep CNS expertise as vital for advancing vidofludimus calcium toward regulatory approval & commercial launch.
  • Congleton emphasized the potential of vidofludimus calcium to offer neuroprotective, anti-inflammatory, & anti-viral advantages for MS patients.
  • Vidofludimus calcium is currently in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026.
  • The drug functions as a first-in-class Nurr1 activator while selectively inhibiting the enzyme DHODH.
  • Immunic's pipeline also includes earlier-stage programs IMU-856 & IMU-381 targeting neurodegenerative, chronic inflammatory, & autoimmune diseases.
  • The press release includes standard forward-looking statement disclaimers regarding clinical trial results, regulatory approvals, & financial projections.